Last reviewed · How we verify

NCT07162649

Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults

Not yet recruiting NA Last updated 9 September 2025
What this trial tests

NA trial testing Dexmedetomidine in Dexmedetomidine in 400 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
30 August 2027
30 August 2028

Quick facts

Lead sponsorYuan Shen
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment400
Start date1 September 2025
Primary completion30 August 2027
Estimated completion30 August 2028

Drugs / interventions tested

Conditions studied

Sponsor

Yuan Shen — full company profile →

Who can join

Adults 18 to 65, any sex, with Dexmedetomidine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an α₂-adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Dexmedetomidine

Currently open trials in the same condition.

Other Yuan Shen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07162649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing